智通财经APP讯,复星医药(600196.SH)发布公告,近日,公司控股子公司成都星睿菁烜生物科技有限公司(简称“星睿菁烜”)收到国家药品监督管理局关于同意[ 18F]F-SR031 注射液(简称“SRT-003-1”)用于实体瘤患者成纤维细胞活化蛋白(FAP)阳性病灶正电子发射断层扫描(PET)显像的临床试验批准。星睿菁烜拟于条件具备后于中国境内开展该药品的 I 期临床研究。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.